tert-butyl (2-(2-chloroethoxy)ethoxy)dimethylsilane | 119382-85-3

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: tert-butyl (2-(2-chloroethoxy)ethoxy)dimethylsilane
• 英文别名: tert-butyl[2-(2-chloroethoxy)ethoxy]dimethylsilane；tert-butyl-[2-(2-chloro-ethoxy)-ethoxy]-dimethyl-silane；2-[2-(t-butyldimethylsilyloxy)ethoxy]ethyl chloride；Tert-butyl(2-(2-chloroethoxy)ethoxy)dimethylsilane；tert-butyl-[2-(2-chloroethoxy)ethoxy]-dimethylsilane
• CAS: 119382-85-3
• 化学式: C₁₀H₂₃ClO₂Si
• 分子量: 238.83
• InChiKey: DWHGPCNQEAWRBW-UHFFFAOYSA-N

物化性质

• 沸点：
  236.3±15.0 °C(Predicted)
• 密度：
  0.942±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.26
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tert-butyl (2-(2-chloroethoxy)ethoxy)dimethylsilane 、 对羟基苯甲醛 在 [Ir(dF(CF₃)ppy)₂(dtbbpy)](PF₆) 、 Selectfluor 作用下， 以 乙腈 为溶剂， 反应 10.5h， 以78%的产率得到2-(2-chloroethoxy)ethyl 4-hydroxybenzoate
  参考文献：
  名称：

  单步双官能化：羟基苯甲醛与 CCl3Br 的一锅溴化-交叉脱氢酯化 - 与 Selectfluor 的比较

  摘要：

  不直接使用分子溴对酚类化合物进行溴化具有重要意义。本文报道了 IrIII/CCl3Br 辅助的羟基苯甲醛单步双官能化。它涉及在一锅中同时进行醛基酯化和酚醛芳环的溴化。在 445 nm 蓝光 LED 光的存在下，反应在温和条件下进行，以中等至良好的产率获得高度官能化的溴羟基苯甲酸酯。相比之下，Selectfluor 作为氧化剂只产生非溴酚酸酯。

  DOI：

  10.1055/s-0037-1610717
• 作为产物：
  描述：

  叔丁基二甲基氯硅烷 、 2-氯乙氧基乙醇 在 咪唑 作用下， 以 乙腈 为溶剂， 以92%的产率得到tert-butyl (2-(2-chloroethoxy)ethoxy)dimethylsilane
  参考文献：
  名称：

  Benzopyran or thiobenzopyran derivatives

  摘要：

  本发明提供了新颖的苯并吡喃化合物，其药学上可接受的盐及其立体异构体，其中本发明的苯并吡喃化合物是根据式I的化合物：本发明还提供了具有抗雌激素活性的药物组合物，包括本发明的至少一种苯并吡喃化合物，并通过给予本发明提供的苯并吡喃化合物的有效量来治疗乳腺癌的方法。

  公开号：

  US06645951B1

文献信息

• THIAZOLIDINONE COMPOUNDS AND USE THEREOF
  申请人：National Health Research Institutes

  公开号：US20170253569A1

  公开（公告）日：2017-09-07

  A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

  一种含有化合物（I）的药物组合物，用于治疗与阿片受体相关的疾病。还公开了一种使用这种化合物治疗阿片受体相关疾病的方法。进一步公开了两组式（I）的噻唑烷酮化合物：（i）每种化合物的对映体过量大于90%；（ii）每种化合物被氘取代。
• [EN] SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS<br/>[FR] DÉRIVÉS 4,5,6,7-TÉTRAHYDRO-PYRAZOLO[1,5-A]PYRAZINE SUBSTITUÉS ET DÉRIVÉS 5,6,7,8-TÉTRAHYDRO-4H-PYRAZOLO[1,5-A][1,4]DIAZÉPINE UTILISÉS COMME INHIBITEURS DE ROS1
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2015144799A1

  公开（公告）日：2015-10-01

  The present invention relates to substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives of formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS 1 inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及取代的4,5,6,7-四氢吡唑并[1,5-a]吡嗪衍生物和5,6,7,8-四氢-4H-吡唑并[1,5-a][1,4]二氮杂环衍生物的公式(I)中的变量具有权利要求中定义的含义。根据本发明的化合物可用作ROS 1抑制剂。本发明还涉及制备这种新化合物的方法，包含所述化合物作为活性成分的药物组合物，以及将所述化合物用作药物的用途。
• Cross-Dehydrogenating Coupling of Aldehydes with Amines/R-OTBS Ethers by Visible-Light Photoredox Catalysis: Synthesis of Amides, Esters, and Ureas
  作者：Ganesh Pandey、Suvajit Koley、Ranadeep Talukdar、Pramod Kumar Sahani

  DOI：10.1021/acs.orglett.8b02537

  日期：2018.9.21

  A straightforward synthesis of amides, ureas, and esters is reported by visible-light cross-dehydrogenating coupling (CDC) of aldehydes (or amine carbaldehydes) and amines/R-OTBS ethers by photoredox catalysis. The reaction is found to be general and high yielding. A plausible mechanistic pathway has been proposed for these transformations and is supported by appropriate controlled experiments.

  通过光氧化还原催化醛（或胺甲醛）和胺/ R-OTBS醚的可见光交叉脱氢偶联（CDC），报道了酰胺，脲和酯的直接合成。发现该反应是一般的且高收率的。已经为这些转化提出了一种可行的机理途径，并得到了适当的受控实验的支持。
• Thiazolidin-4-one derivatives useful for treating diseases caused by
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：US04992455A1

  公开（公告）日：1991-02-12

  Thiazolidin-4-one derivative represented by the folowing general formula (I) and acid addition salts thereof ##STR1## wherein; R.sup.1 and R.sup.2 are the same or different and denote each (i) a residue represented by the general formula --A--R.sup.4 wherein, A denotes a single bond, C.sub.1 -C.sub.8 alkylene, C.sub.2 -C.sub.8 alkenylene, or C.sub.2 -C.sub.8 alkynylene and R.sup.4 denotes hydrogen, C.sub.1 -C.sub.12 alkyl, C.sub.2 -C.sub.8 alkenyl, C.sub.3 -C.sub.8 cycloalkyl, or C.sub.1 -C.sub.6 haloalkyl, or (ii) a residue represented by the general formula (CH.sub.2).sub.n O}.sub.m (CH.sub.2).sub.n' O}B--R.sup.5 wherein, B denotes a single bond or C.sub.1 -C.sub.6 alkylene, R.sup.5 denotes hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.8 alkenyl, C.sub.3 -C.sub.8 cycloalkyl, substituted silyl, or substituted or unsubstituted aryl, n and n' denote each an integer of 2 to 4, m denotes an integer of 1 to 3, and m' denotes an integer of 0 to 2; and R.sup.3 denotes hydrogen, C.sub.1 -C.sub.2 alkyl, allyl, 2-propynyl, or a residue represented by (a) the general formula --CH.sub.2).sub.l R.sup.6 wherein, R.sup.6 denotes halogen, an aryl group substituted or unsubstituted by one or more hydroxy or C.sub.1 -C.sub.4 alkoxy groups, or a residue represented by the general formula --D--R.sup.7 (D denotes oxygen or sulfur and R.sup.7 denotes hydrogen, C.sub.1 -C.sub.4 alkyl, or C.sub.1 -C.sub.4 alkanol) and l denotes an integer of 2 to 4, (b) the general formula --CH.sub.2).sub.k CO--E--R.sup.8 wherein, E denotes oxygen, sulfur, imino, or C.sub.1 -C.sub.4 alkylimino, R.sup.8 denotes hydrogen or C.sub.1 -C.sub.4 alkyl, or --(E--R.sup.8) denotes a 5- to 7-membered cyclic amino group which optionally contains other hetero atoms, and k denotes an integer of 1 to 3, or (c) the general formula --F--R.sup.9 wherein, F denotes C.sub.2 -C.sub.6 alkylene and R.sup.9 denotes a nitrogen-containing heterocyclic aromatic residue or an amino group represented by the general formula ##STR2## (R.sup.10 denotes hydrogen, C.sub.1 -C.sub.4 alkyl, or C.sub.1 -C.sub.4 alkyl or R.sup.10 in combination with R.sup.11 denotes a 5- to 7-membered cyclic amino group which optionally contains other hetero atoms), with the proviso that, when R.sup.1 is hydrogen and R.sup.2 is methyl, R.sup.3 denotes hydrogen, C.sub.1 -C.sub.2 alkyl, 2-propynyl, or a residue represented by (a) the general formula --CH.sub.2).sub.l R.sup.6 wherein, R.sup.6 denotes halogen, an aryl group substituted or unsubstituted by one or more hydroxy or C.sub.1 -C.sub.4 alkoxy groups, or a residue represented by the general formula --D--R.sup.7 (D denotes oxygen or sulfur and R.sup.7 denotes hydrogen, C.sub.1 -C.sub.4 alkyl, or C.sub.1 -C.sub.4 alkanoyl) and l denotes an integer of 2 to 4, (b) the general formula --CH.sub.2).sub.k CO--E--R.sup.8 wherein, E denotes oxygen, sulfur, imino, or C.sub.1 -C.sub.4 alkylimino, R.sup.8 denotes hydrogen or C.sub.1 -C.sub.4 alkyl, or --(E--R.sup.8) denotes a 5- to 7-membered cyclic amino group which optionally contains other hetero atoms, and k denotes an integer of 1 to 3, or (c) the general formula --F--R.sup.9 wherein, F denotes C.sub.2 -C.sub.6 alkylene and R.sup.9 denotes a nitrogen-containing heterocyclic aromatic residue or an amino group represented by the general formula ##STR3## (R.sup.10 denotes hydrogen, C.sub.2 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkanoyl and R.sup.11 denotes hydrogen or C.sub.1 -C.sub.4 alkyl or R.sup.10 in combination with R.sup.11 denotes a 5- to 7-membered cyclic amino group which optionally contains other hetero atoms. Having selective PAF-antagonistic activities, these compounds are very useful as preventive and curative agents for PAF-induced diseases, for example, various kinds of inflammation, allergic diseases, circulatory diseases, and gastro-intestinal diseases.

  以下为一般式（I）所表示的噻唑烷-4-酮衍生物及其酸加成盐： 其中，R1和R2相同或不同，分别表示（i）由一般式-A-R4表示的残基，其中A表示单键，C1-C8烷基，C2-C8烯基或C2-C8炔基，R4表示氢，C1-C12烷基，C2-C8烯基，C3-C8环烷基或C1-C6卤代烷基，或（ii）由一般式（（CH2）nO）m（（CH2）n' O）B-R5表示的残基，其中B表示单键或C1-C6烷基，R5表示氢，C1-C6烷基，C2-C8烯基，C3-C8环烷基，取代硅基或取代或未取代芳基，n和n'分别表示2至4的整数，m表示1至3的整数，m'表示0至2的整数；R3表示氢，C1-C2烷基，烯丙基，2-丙炔基或由以下表示的残基：（a）一般式-（CH2）lR6，其中，R6表示卤素，被一个或多个羟基或C1-C4烷氧基取代或未取代的芳基基团，或由一般式-D-R7表示的残基（D表示氧或硫，R7表示氢，C1-C4烷基或C1-C4烷醇基），l表示2至4的整数；（b）一般式-（CH2）kCO-E-R8，其中，E表示氧，硫，亚胺或C1-C4烷基亚胺，R8表示氢或C1-C4烷基，或-（E-R8）表示可选含有其他杂原子的5-至7元环胺基团，k表示1至3的整数；或（c）一般式-F-R9，其中，F表示C2-C6烷基，R9表示含氮杂环芳基残基或由以下一般式表示的氨基团：（其中，R10表示氢，C1-C4烷基或C1-C4烷基，或R10与R11组合表示可选含有其他杂原子的5-至7元环胺基团），但当R1为氢，R2为甲基时，R3表示氢，C1-C2烷基，2-丙炔基或由以下表示的残基：（a）一般式-（CH2）lR6，其中，R6表示卤素，被一个或多个羟基或C1-C4烷氧基取代或未取代的芳基基团，或由一般式-D-R7表示的残基（D表示氧或硫，R7表示氢，C1-C4烷基或C1-C4烷酰基），l表示2至4的整数；（b）一般式-（CH2）kCO-E-R8，其中，E表示氧，硫，亚胺或C1-C4烷基亚胺，R8表示氢或C1-C4烷基，或-（E-R8）表示可选含有其他杂原子的5-至7元环胺基团，k表示1至3的整数；或（c）一般式-F-R9，其中，F表示C2-C6烷基，R9表示含氮杂环芳基残基或由以下一般式表示的氨基团：（其中，R10表示氢，C2-C4烷基或C1-C4烷酰基，R11表示氢或C1-C4烷基或R10与R11组合表示可选含有其他杂原子的5-至7元环胺基团）。这些化合物具有选择性PAF-拮抗活性，非常有用作为PAF诱导疾病的预防和治疗剂，例如各种炎症，过敏疾病，循环系统疾病和胃肠疾病。
• Thiazolidin-4-one derivatives and acid addition salts thereof useful for
  申请人：Sumitomo Chemical Company, Limited

  公开号：US05106860A1

  公开（公告）日：1992-04-21

  Thiazolidin-4-one derivative represented by the following general formula (I) and acid addition salts thereof ##STR1## wherein; R.sup.1 and R.sup.2 are the same or different and denote each (i) a residue represented by the general formula --A--R.sup.4 wherein, A denotes a single bond, C.sub.1 -C.sub.8 alkylene, C.sub.2 -C.sub.8 alkenylene, or C.sub.2 -C.sub.8 alkynylene and R.sup.4 denotes hydrogen, C.sub.1 -C.sub.12 alkyl, C.sub.2 -C.sub.8 alkenyl, C.sub.3 -C.sub.8 cycloalkyl, or C.sub.1 -C.sub.6 haloalkyl,or (ii) a residue represented by the general formula ##STR2## wherein, B denotes a single bond or C.sub.1 -C.sub.6 alkylene, R.sup.5 denotes hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.8 alkenyl, C.sub.3 -C.sub.8 cycloalkyl, substituted silyl, or substituted or unsubstituted aryl, n and n' denote each an integer of 2 to 4, m denotes an integer of 1 to 3, and m' denotes an integer of 0 to 2; R.sup.3 denotes hydrogen, C.sub.1 -C.sub.2 alkyl, allyl, 2-propynyl, or (c) the general formula --F--R.sup.9 wherein, F denotes C.sub.2 -C.sub.6 alkylene and R.sup.9 denotes a nitrogen-containing heterocyclic aromatic residue or an amino group represented by the general formula ##STR3## (R.sup.10 denotes hydrogen, C.sub.2 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkanoyl and R.sup.11 denotes hydrogen or C.sub.1 -C.sub.4 alkyl or R.sup.10 in combination with R.sup.11 denotes a 5- to 7-membered cyclic amino group which optionally contains other hetero atoms. Having selective PAF-antagonistic activities, these compounds are very useful as preventive and curative agents for PAF-induced diseases, for example, various kinds of inflammation, allergic diseases, circulatory diseases, and gastro-intestinal diseases.

  以下是由下列一般式（I）表示的噻唑烷-4-酮衍生物及其酸加成盐：##STR1## 其中，R.sup.1和R.sup.2相同或不同，分别表示（i）由一般式--A--R.sup.4表示的残基，其中，A表示单键，C.sub.1-C.sub.8烷基，C.sub.2-C.sub.8烯基或C.sub.2-C.sub.8炔基，而R.sup.4表示氢，C.sub.1-C.sub.12烷基，C.sub.2-C.sub.8烯基，C.sub.3-C.sub.8环烷基或C.sub.1-C.sub.6卤代烷基；或（ii）由下列一般式表示的残基：##STR2## 其中，B表示单键或C.sub.1-C.sub.6烷基，R.sup.5表示氢，C.sub.1-C.sub.6烷基，C.sub.2-C.sub.8烯基，C.sub.3-C.sub.8环烷基，取代硅烷基或取代或未取代芳基，n和n'分别表示2到4的整数，m表示1到3的整数，而m'表示0到2的整数；R.sup.3表示氢，C.sub.1-C.sub.2烷基，烯丙基，2-丙炔基或由下列一般式表示的残基--F--R.sup.9，其中，F表示C.sub.2-C.sub.6烷基，而R.sup.9表示含氮杂环芳基残基或由下列一般式表示的氨基：##STR3## （其中，R.sup.10表示氢，C.sub.2-C.sub.4烷基或C.sub.1-C.sub.4酰基，而R.sup.11表示氢或C.sub.1-C.sub.4烷基，或R.sup.10与R.sup.11组合表示可选地含有其他杂原子的5-至7-成员环氨基。）这些化合物具有选择性的PAF-拮抗活性，非常有用作为预防和治疗PAF引起的疾病，例如各种炎症，过敏性疾病，循环系统疾病和胃肠疾病的药物。